Sep 29, 2026 | Legal Compliance
The U.S. Food and Drug Administration (FDA) issued a warning letter dated September 18, 2026 to Houston-based Empower Clinic Services, LLC d/b/a Empower Pharmacy and its CEO, Arta Shaun Noorian. Following a November 3 to 14, 2025 inspection of its Houston facility,...
Sep 16, 2026 | Legal Compliance, State-Specific Regulations, Technology & Privacy
California is updating its health care regulatory framework to address the rapid integration of artificial intelligence in clinical environments. With the passage of Assembly Bill No. 3030 (AB 3030), the state has established clear disclosure standards for health care...
Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
Sep 1, 2026 | Legal Compliance, News, State-Specific Regulations
Mississippi’s three healthcare licensing boards have put the state’s providers on notice: there is no safe harbor for offering “research-grade” peptides to patients. In a joint statement issued by the Mississippi State Board of Medical...
Aug 13, 2026 | Legal Compliance
In 2025, the Fifth Circuit’s Zyla Life Sciences, LLC v. Wells Pharma of Houston, LLC included a passing, non-binding comment suggesting that brand-name manufacturers might sue compounders under state unfair-competition laws for selling unapproved “new...
Aug 13, 2026 | Legal Compliance, News
Eli Lilly & Co. has significantly escalated its legal campaign against the illicit trade of its investigational weight-loss drug, retatrutide. The pharmaceutical giant filed lawsuits in federal court against six U.S.-based businesses—including medical spas,...
